Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EBT (2016 - 2025)

Haemonetics has reported EBT over the past 17 years, most recently at $60.0 million for Q4 2025.

  • Quarterly results put EBT at $60.0 million for Q4 2025, up 20.15% from a year ago — trailing twelve months through Dec 2025 was $227.2 million (up 37.89% YoY), and the annual figure for FY2025 was $212.1 million, up 39.64%.
  • EBT for Q4 2025 was $60.0 million at Haemonetics, up from $51.3 million in the prior quarter.
  • Over the last five years, EBT for HAE hit a ceiling of $70.7 million in Q1 2025 and a floor of -$27.4 million in Q2 2021.
  • Median EBT over the past 5 years was $41.6 million (2022), compared with a mean of $34.9 million.
  • Biggest five-year swings in EBT: plummeted 224.76% in 2021 and later surged 947.54% in 2022.
  • Haemonetics' EBT stood at $19.9 million in 2021, then surged by 111.95% to $42.2 million in 2022, then increased by 4.27% to $44.0 million in 2023, then increased by 13.37% to $49.9 million in 2024, then grew by 20.15% to $60.0 million in 2025.
  • The last three reported values for EBT were $60.0 million (Q4 2025), $51.3 million (Q3 2025), and $45.2 million (Q2 2025) per Business Quant data.